Holen Sie sich die Stockscreener-App
217.72
8.04%
-18.35
Schlusskurs vom Vortag:
$236.07
Offen:
$226.138
24-Stunden-Volumen:
764.55K
Relative Volume:
0.83
Marktkapitalisierung:
$15.28B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
66.26
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
-8.40%
1M Leistung:
-10.56%
6M Leistung:
-36.48%
1J Leistung:
-11.27%
1-Tages-Spanne:
$217.00
$230.43
1-Wochen-Bereich:
$217.00
$241.90
52-Wochen-Spanne:
$217.00
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
217.10 | 16.62B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
107.81 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
340.52 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.42 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.69 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.18 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Insulet Corporation (PODD) Announces Voluntary Medical Device Co - GuruFocus
INSULET recalls specific Omnipod 5 pods due to insulin leak risk - StreetInsider
Insulet (PODD) Addresses Manufacturing Issue in Omnipod 5 Pods - GuruFocus
Insulet Issues Voluntary Omnipod 5 Device Correction - TipRanks
Insulet recalls specific Omnipod 5 insulin pump lots after injuries - Investing.com
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S. - Business Wire
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System - Medical Product Outsourcing
Swiss National Bank Reduces Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Holdings Boosted by Capital Fund Management S.A. - MarketBeat
Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness - simplywall.st
Insulet (PODD) AID System Shows Promise in Diabetes Management - GuruFocus
Insulet presents study results for fully closed-loop automated insulin delivery system - marketscreener.com
Insulet Reports Positive Results From Automated Insulin Pump Trial - marketscreener.com
Insulet reports positive results for closed-loop diabetes system - StreetInsider
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes - Business Wire
Insulet (PODD): Citigroup Adjusts Price Target Amid Buy Rating | - GuruFocus
Magnetar Financial LLC Has $7.12 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Citigroup Adjusts Price Target on Insulet to $338 From $345, Maintains Buy Rating - marketscreener.com
Korea Investment CORP Sells 17,419 Shares of Insulet Corporation $PODD - MarketBeat
Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - BioSpace
Insulet Corporation $PODD Shares Sold by Capital Research Global Investors - MarketBeat
Vinva Investment Management Ltd Makes New Investment in Insulet Corporation $PODD - MarketBeat
Avoiding Lag: Real-Time Signals in (PODD) Movement - Stock Traders Daily
Published on: 2026-03-09 05:40:12 - baoquankhu1.vn
Rhenman & Partners Asset Management AB Grows Stock Position in Insulet Corporation $PODD - MarketBeat
Blair William & Co. IL Sells 20,182 Shares of Insulet Corporation $PODD - MarketBeat
Insulet stock: Is the Omnipod maker your next stealth growth play? - AD HOC NEWS
Insulet Corporation (PODD) Finalizes Severance Agreement with Fo - GuruFocus
Fisher Asset Management LLC Has $14.29 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Finalizes Severance Terms for Departing CFO - TipRanks
Former Insulet (NASDAQ: PODD) CFO Ana Chadwick signs severance deal - Stock Titan
Mass. biotech giants added workers in 2025 despite industry-wide layoffs - The Business Journals
Insulet (PODD) SVP Prem Singh reports tax-withholding share transactions - Stock Titan
Insulet (PODD) SVP uses 253 shares to cover RSU tax withholding - Stock Titan
Insulet (PODD) executive records Form 4 tax-withholding share dispositions - Stock Titan
Insulet Corp (NASDAQ: PODD) SVP withholds 605 shares for taxes - Stock Titan
Insulet (PODD) EVP and COO logs tax-withholding share moves in Form 4 - Stock Titan
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Segall Bryant & Hamill LLC Boosts Position in Insulet Corporation $PODD - MarketBeat
CI Investments Inc. Grows Stock Position in Insulet Corporation $PODD - MarketBeat
William Blair Investment Management LLC Sells 289,636 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Stock Analysis: Exploring a Promising 43.71% Upside in the Medical Devices Sector - DirectorsTalk Interviews
TD Asset Management Inc Has $12.22 Million Stake in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (NASDAQ:PODD) Short Interest Down 21.8% in February - MarketBeat
Insulet Corporation $PODD Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Strong Revenue Growth And Upbeat 2026 Outlook Might Change The Case For Investing In Insulet (PODD) - simplywall.st
PODD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quantbot Technologies LP Cuts Position in Insulet Corporation $PODD - MarketBeat
American Century Companies Inc. Sells 106,813 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation's 10th Straight Year Above 20% Revenue Growth Raises Expectations - Smartkarma
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):